Brind.

Revolution Medicines and Iambic Therapeutics announced a collaboration to develop targeted therapies for RAS-addicted cancers using AI discovery tools.

1 report, 1 independent Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Revolution Medicines and Iambic Therapeutics announced a collaboration to develop targeted therapies for RAS-addicted cancers using AI discovery tools.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireRevolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates Custom-built model will be trained using Revolution Medi